MyAlcon | United Kingdom
This page is available in English. Select below for other countries.
MyAlcon | Country
COMING SOON
Americas
Brazil
Mexico
Colombia
Chile
Argentina
Ecuador
Peru
Uruguay
Europe / Middle East / Africa
Spain
Italy
France
Asia Pacific
South Korea
China
Hong Kong
Singapore
AcrySof IQ Vivity® IOL
Simplifying
Presbyopia Correction1-9
The First and Only presbyopia-correcting IOL
with wavefront-shaping technology and a
clinically proven monofocal
visual disturbance profile1-4
AcrySof IQ Vivity® IOL
Simplifying Presbyopia Correction1-9
The First and Only presbyopia-correcting IOL with wavefront-shaping technology and a clinically proven monofocal visual disturbance profile1-4
Results from 2 Large Independent Trials:
AcrySof IQ Vivity® IOL Delivers Excellent Distance, Intermediate
and Functional Near Vision3,4


20/20
Binocular Mean
Uncorrected Distance
Visual Acuity (4 m)*
DISTANCE


Better Than 20/25
Binocular Mean
Uncorrected Intermediate
Visual Acuity (66 cm)*
INTERMEDIATE


20/32
Binocular Mean
Uncorrected Near
Visual Acuity (40 cm)*
NEAR
* Binocular uncorrected visual acuity results from a prospective, randomised, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 113 with the AcrySof® IQ IOL with 6 months’ follow-up.
In All Light Conditions, AcrySof IQ Vivity® IOL Patients Reported Monofocal-Quality Distance With Excellent Intermediate and Functional Near Vision4
Percent of Patients Reporting Good or Very Good Vision Without Spectacles at 6 Months in Validated IOLSAT Questionnaire4*†

* Patients were asked, “How well did you see without wearing eyeglasses in the past 7 days?”
† Results from a prospective, randomised, parallel group, subject and assessor masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 113 with the AcrySof® IQ IOL with 6 months follow-up.
AcrySof IQ Vivity® IOL Visual Disturbance Profile is Comparable to AcrySof® IQ Monofocal1,3,4
The majority of AcrySof IQ Vivity® IOL patients were not bothered at all by visual disturbances.4
Degree of Bother (%)*

Diffractive trifocal technology IOLs can deliver reduced spectacle dependance, but it's not for every patient. Some patients are not candidates due to low tolerance for visual disturbances or other ocular health problems.10-12
* Results from a prospective, randomised, parallel group, subject and assessor masked, multisite trial of 107 subjects bilaterally implanted with AcrySof IQ Vivity® Extended Vision IOL and 113 with AcrySof® IQ IOL with 6 months follow-up. Visual disturbances were evaluated subjectively through QUVID questionnaire. Patients were asked: “In the past 7 days, how much were you bothered with starbursts, halos, and glare?”
AcrySof IQ Vivity® IOL Halo Profile is Comparable
to AcrySof® IQ Monofocal IOL1-4,7
Optical Bench Halo Measurements (4.5 mm Pupil Size)7


AcrySof® IQ
Monofocal IOL


AcrySof IQ Vivity®
IOL Wavefront-Shaping
Technology


TECNIS* Symfony*
Diffractive EDF


ZEISS* AT LARA*
Diffractive EDF
These are representative images from a benchtop study.
* Trademarks are property of their respective owners.
AcrySof IQ Vivity® IOL is the First and Only presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-4
✓ The AcrySof IQ Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the AcrySof® IQ monofocal1,2
✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2
✓ Surface Transition #2: A small curvature change (across the 2.2 mm region) that shifts the wavefront to utilise all available light energy2

AcrySof IQ Vivity® IOL is the First and Only presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-4
✓ The AcrySof IQ Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the AcrySof® IQ monofocal1,2
✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2
✓ Surface Transition #2: A small curvature change (across the 2.2 mm region) that shifts the wavefront to utilise all available light energy2

AcrySof IQ Vivity® IOL is the First and Only presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-4
✓ The AcrySof IQ Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the AcrySof® IQ monofocal1,2
✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2
✓ Surface Transition #2: A small curvature change (across the 2.2 mm region) that shifts the wavefront to utilise all available light energy2

Unique Mechanism of Action
The AcrySof IQ Vivity® IOL uses wavefront-shaping technology to deliver distance, intermediate, and functional near vision for patients, as well as a clinically proven monofocal visual disturbance profile.1-4
The wavefront-shaping technology of the AcrySof IQ Vivity® IOL is called X-WAVE™ Technology and is proprietary to Alcon.
Wavefront-shaping stretches the light. It doesn’t bend light like refraction, or split light like diffraction.
Just like a monofocal, Vivity® utilises essentially all of the transmitted light energy that passes through the lens. The smooth surface transition elements on the AcrySof IQ Vivity® IOL stretch and shift the wavefront to provide a full range of vision with functional near visual acuity to help reduce spectacle dependence.1-4
Surface Transition Elements Affect Light Energy Distribution*
The proprietary, wavefront-shaping design creates a monofocal visual disturbance profile and a continuous range of vision for patients.1-4
With the AcrySof IQ Vivity® IOL, light spans a continuous focal range, instead of being split amongst multiple focal points.5,13

* Simulated photopic through-focus point spread function (light intensity [energy]) – polychromatic.
† Trademarks are the property of their respective owners.
The Flat Defocus Curve Delivers Confidence in Hitting a Refractive Target With AcrySof IQ Vivity® IOL3
6-Month Binocular Distance Corrected Visual Acuity3*

A refractive miss of +/- 0.5D can still leave
a patient with VA of 20/20
* Adaptation based on data obtained from a prospective, randomised, controlled study of bilateral implantation of 106 AcrySof IQ Vivity® patients and 111 AcrySof® IQ monofocal IOL patients from a computerised visual acuity test system.
6-Month Binocular Distance Corrected Visual Acuity3*

AcrySof IQ Vivity® IOL patients experience a continuous extended
range of vision from distance to as close as 50 cm
See Why Patients Say The AcrySof IQ Vivity® IOL
Was The Right Choice For Them
Leslie, United Kingdom
Leslie is a patient who has been playing tennis for years, the AcrySof IQ Vivity® IOL allowed him to play again with the eye surgeon who implanted the lens, while still reading the newspaper without glasses.1
Antonio, Spain
Antonio is representative of patients who participated in the global AcrySof IQ Vivity® IOL studies, reporting 20/20 distance VA, >20/25 intermediate distance VA (66 cm), and 20/32 near VA (40 cm).1
Maria, Spain
Maria is like many patients who are most suited for a lens with a continuous range of vision in order to maintain their hobbies and active lifestyle.1
Elena, Spain
Elena is an AcrySof IQ Vivity® IOL patient who represents many patients who are considered unsuitable for PCIOLs; these include people with Type A personalities, people who drive at night, and who have mild glaucoma.1
The patients that appear in these videos express opinions that are their own, based on their own experiences.
These videos are not a substitute for medical advice or information.
Clinical Support
NOTE: Available to JCRS subscribers and ACSRS / ESCRS members
Technical Specifications1,2

Instructions for Use (IFU)
For a full list of indications, contraindications and warnings, please visit ifu.alcon.com and refer to the relevant product’s instructions for use.
Alcon Experience Academy
For relevant training content from industry thought leaders
1 . AcrySof IQ Vivity® Extended Vision IOL Directions for Use.
2. Alcon Data on File. US Patent 9968440 B2. 15 May 2018.
3. Bala C, et al. Multi-country clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens. J Cataract Refract Surg. 2021: Ahead of print. doi:10.1097/j.jcrs.0000000000000712
4. Alcon Data on File. TDOC-0055576. 23-Jul-2019
5. Alcon Data on File, TDOC-0056718. 18 Jun 2019.
6. Ligabue E, et al. ACRYSOF IQ VIVITY: Natural vision at a range of distances provided by a novel optical technology. Cataract & Refractive Surgery Today. April 2020.
7. Alcon Data on File. A02062-REP-043696, Optical Evaluations of Alcon Vivity®, Symfony*, and Zeiss* AT LARA* IOLs.
8. Lawless M. Insight news. “An IOL to change the cataract surgery paradigm?” available at “https://insightnews.com.au/an-iol-to-change-the-cataract-surgery-paradigm/”. Accessed 17 Jul 2020.
9. Ike K. Ahmed, et al. The Vivity Extended Depth of Focus IOL: Our Clinical Experience. Cataract & Refractive Surgery Today. February 2021//
10. Braga-Mele R, et al. Multifocal intraocular lenses: relative indications and contraindications for implantation. J Cataract Refract Surg. 2014;40(2):313-322.
11. Gundersen KG, et al. Retreatments after multifocal intraocular lens implantation: an analysis. Clin Ophthalmol. 2016:10;365–371.
12. Zvornicanin J, et al. Premium intraocular lenses: The past, present and future. J Curr Ophthalmol. 2018;30(4):287-296.
13. Alcon Internal Memo, September 2020. REF-12576
For indications, contraindications and warnings, please refer to the relevant product's instruction for use. Find at: https://ifu.alcon.com/
©2022 Alcon Inc. 02/22 UKIE-VIV-2200001